Acquisition by Arthur Taveras of 230645 shares of X4 Pharmaceuticals subject to Rule 16b-3
| BCTX Stock | USD 4.18 0.08 1.95% |
Slightly above 53% of Briacell Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Briacell Therapeutics Corp suggests that many traders are impartial. Briacell Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Briacell Therapeutics' earnings reports, geopolitical events, and overall market trends.
Briacell |
Filed transaction by X4 Pharmaceuticals Officer: Chief Scientific Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Briacell Therapeutics Fundamental Analysis
We analyze Briacell Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Briacell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Briacell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Briacell Therapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Briacell Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Briacell Therapeutics stock to make a market-neutral strategy. Peer analysis of Briacell Therapeutics could also be used in its relative valuation, which is a method of valuing Briacell Therapeutics by comparing valuation metrics with similar companies.
Peers
Briacell Therapeutics Related Equities
| PDSB | PDS Biotechnology | 22.22 | ||||
| HEPA | Hepion Pharmaceuticals | 6.67 | ||||
| ELEV | Elevation Oncology | 1.85 | ||||
| INZY | Inozyme Pharma | 1.68 | ||||
| TERN | Terns Pharmaceuticals | 1.35 | ||||
| MREO | Mereo BioPharma | 2.78 | ||||
| XFOR | X4 Pharmaceuticals | 6.82 | ||||
| HOOK | Hookipa Pharma | 7.36 | ||||
| DAWN | Day One | 16.50 |
Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.